Prevalence and genotype distribution of HPV and cervical pathological results in Sichuan Province, China: a three years surveys prior to mass HPV vaccination

Luo, Qing; Jiang, Ni; Wu, Qiaoyuan; Wang, Jiaqiang; Zhong, Jialing

doi:10.1186/s12985-020-01366-2

Virology Journal

Table 3 Prevalence of HPV genotypes in HPV-positive population

From: Prevalence and genotype distribution of HPV and cervical pathological results in Sichuan Province, China: a three years surveys prior to mass HPV vaccination

	Total HPV+				HEC HPV+				OGOC HPV+				p^a
	S%^c (n = 2478)	M%^d (n = 904)	T%^e (n = 3382)	CI (95%) (n = 3382)	S%^c (n = 1052)	M%^d (n = 267)	T%^e (n = 1319)	CI (95%) (n = 1319)	S%^c (n = 1426)	M%^d (n = 637)	T%^e (n = 2063)	CI (95%) (n = 2063)	p^a
High Risk
16	8.10	5.50	13.60	12.45–14.76	5.98	3.44	9.42	7.85–10.98	9.49	6.85	16.34	14.74–17.94	< 0.001^b
18	2.28	2.69	4.97	4.24–5.70	2.24	1.79	4.04	2.98–5.09	2.30	3.28	5.58	4.58–6.57	0.044^b
31	1.77	1.77	3.55	2.92–4.17	1.79	1.27	3.06	2.14–3.99	1.76	2.10	3.86	3.03–4.70	0.218
33	2.75	2.28	5.03	4.29–5.76	3.21	1.42	4.63	3.51–5.76	2.45	2.84	5.28	4.31–6.25	0.398
35	0.50	0.59	1.09	0.74–1.44	0.75	0.45	1.20	0.61–1.78	0.34	0.68	1.03	0.59–1.46	0.645
39	4.82	4.46	9.28	8.31–10.26	5.53	3.44	8.97	7.44–10.50	4.35	5.14	9.49	8.22–10.76	0.609
45	0.33	0.68	1.01	0.67–1.34	0.45	0.52	0.97	0.45–1.50	0.24	0.78	1.03	0.59–1.46	0.874
51	3.78	4.70	8.52	7.57–9.46	4.71	3.36	8.07	6.61–9.53	3.18	5.58	8.81	7.58–10.03	0.454
52	12.89	8.16	21.05	19.68–22.43	14.13	6.80	20.93	18.75–23.11	12.08	9.05	21.14	19.37–22.90	0.884
53	6.80	5.32	12.12	11.02–13.22	9.49	4.26	13.75	11.91–15.60	5.04	6.02	11.06	9.70–12.42	0.019^b
56	1.21	1.86	3.08	2.49–3.66	1.12	1.27	2.39	1.57–3.21	1.27	2.25	3.52	2.72–4.32	0.063
58	9.05	6.09	15.14	13.93–16.35	9.42	5.01	14.42	12.54–16.31	8.81	6.80	15.61	14.03–17.18	0.348
59	1.12	1.27	2.40	1.88–2.91	0.90	0.97	1.87	1.14–2.59	1.27	1.47	2.74	2.03–3.45	0.105
66	1.98	2.25	4.23	3.55–4.91	2.54	1.42	3.96	2.92–5.01	1.61	2.79	4.40	3.51–5.29	0.532
68	2.40	2.72	5.12	4.37–5.86	2.77	2.32	5.08	3.91–6.26	2.15	2.98	5.14	4.18–6.09	0.944
Low Risk
6	2.96	3.64	6.62	5.79–7.46	0.82	0.90	1.72	1.02–2.42	4.35	5.48	9.83	8.54–11.12	< 0.001^b
11	2.40	2.87	5.26	4.51–6.02	1.05	0.67	1.72	1.02–2.42	3.28	4.26	7.58	6.44–8.73	< 0.001^b
42	0.06	0.30	0.35	0.15–0.56	0.07	0.00	0.07	−0.07 ~ 0.22	0.05	0.49	0.54	0.22–0.86	0.055
43	0.18	0.30	0.47	0.24–0.70	0.15	0.07	0.22	−0.03-0.48	0.20	0.44	0.64	0.29–0.98	0.088
44	1.01	0.98	1.98	1.51–2.45	1.42	1.05	2.47	1.64–3.30	0.73	0.93	1.66	1.11–2.22	0.101
CP8304	6.89	6.21	13.10	11.96–14.24	10.09	5.23	15.32	13.39–17.25	4.79	6.85	11.64	10.25–13.03	p = 0.002^b

^a: HEC group versus OGOC (p value from Pearson’s χ² test)
^b: Statistical significance
^c: women of single genotype infection;
^d: women of multiple genotypes infection;
^e: Total women

Back to article page

ISSN: 1743-422X

Contact us

Submission enquiries: journalsubmissions@springernature.com